Paradigm Biopharmaceuticals

Formed in 2011, Paradigm Biopharmaceuticals had every interest in meeting very significant unmet medical needs and was molded into a major biopharmaceutical innovator. On its journey into the realm of drug development, it started off on the pathway of drug repurposing at which this company has been consolidating its growth. The turning point arrived with the in-licensing of its lead product, Pentosan Polysulfate Sodium, initially proposed for the treatment of interstitial cystitis but with outstanding potential against osteoarthritis and other inflammatory disorders. It was this acquisition that provided the defining moment which launched the company into the mainstream arena in the biopharmaceutical sector. The company worked its way through Phase I and Phase II, completing the latter in 2023. What was pleasing is not just that there was a reduction in pain, but that the reduction was sustained longer over time and that Zilosul resulted in an improvement in the cartilage thickness and volume. Zilosul is not just another form of short-term pain relief, or even longer-term pain relief (although of course it does relieve pain), but it regenerates joint tissues in a way that existing treatments do not.